Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials

American Journal of Cardiology

Volumn 115, Issue 4, 2015, Pages 447-453

  Hsue, Priscilla Y ^a   Bittner, Vera A ^b   Betteridge, John ^c   Fayyad, Rana ^d   Laskey, Rachel ^d   Wenger, Nanette K ^e   Waters, David D ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d PFIZER INC   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; LIPID; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEALTH; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOBAL HEALTH; HEPTANOIC ACIDS; HUMANS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; SEX FACTORS;

EID: 84921883422     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.11.026     Document Type: Article

References (20)

1. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
3. J.M. Walsh, and M. Pignone Drug treatment of hyperlipidemia in women JAMA 291 2004 2243 2252
4. S. Mora, R.J. Glynn, J. Hsia, J.G. MacFadyen, J. Genest, and P.M. Ridker Statins for primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women in primary prevention trials Circulation 121 2010 1069 1077
5. J. Gutierrez, G. Ramirez, T. Rundek, and R.L. Sacco Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis Arch Intern Med 172 2012 909 919
6. W.J. Kostis, J.Q. Cheng, J.M. Dobrzynski, J. Cabrera, and J.B. Kostis Meta-analysis of statin effects in women versus men J Am Coll Cardiol 59 2012 572 582
7. H. Caspard, A.K. Chan, and A.M. Walker Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia Clin Ther 127 2005 1639 1646
8. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, N.K. Wenger Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
9. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek, J. Tsai Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
10. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, L.B. Goldstein, M. Hennerici, A.E. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K.M. Welch, J.A. Zivin Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
11. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
12. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
13. P.S. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
14. H. Naci, J.J. Brugts, R. Fleurence, and A.E. Ades Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials Eur J Prev Cardiol 20 2013 658 670
15. L. Mosca, E.J. Benjamin, K. Berra, J.L. Bezanson, R.J. Dolor, D.M. Lloyd-Jones, L.K. Newby, I.L. Piña, V.L. Roger, L.J. Shaw, D. Zhao, T.M. Beckie, C. Bushnell, J. D'Armiento, P.M. Kris-Etherton, J. Fang, T.G. Ganiats, A.S. Gomes, C.R. Gracia, C.K. Haan, E.A. Jackson, D.R. Judelson, E. Kelepouris, C.J. Lavie, A. Moore, N.A. Nussmeier, E. Ofili, S. Oparil, P. Ouyang, V.W. Pinn, K. Sherif, S.C. Smith Jr., G. Sopko, N. Chandra-Strobos, E.M. Urbina, V. Vaccarino, and N.K. Wenger Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association Circulation 123 2011 1243 1262
16. L.B. Goldstein, P. Amarenco, M. Lamonte, S. Gilbert, M. Messig, A. Callahan, M. Hennerici, H. Sillesen, K.M. Welch SPARCL Investigators Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study Stroke 39 2008 2444 2448
17. J. Armitage The safety of statins in clinical practice Lancet 370 2007 1781 1790
18. S.S. Tomlinson, and K.K. Mangione Potential adverse effects of statins on muscle Phys Ther 85 2005 459 465
19. D.D. Waters, J.E. Ho, D.A. DeMicco, A. Breazna, B.J. Arsenault, W. Chuan-Chuan, J.J. Kastelein, H. Colhoun, and P. Barter Predictors of new-onset diabetes in patients treated with atorvastatin. Results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
20. A.K. Gupta, B. Dahlof, J. Dobson, P.S. Sever, H. Wedel, N.R. Poulter Anglo-Scandinavian Cardiac Outcomes Trial Investigators Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm and the relative influence of antihypertensive medication Diabetes Care 31 2008 982 988